Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Christoph Rummelt; Olga Grishina; Claudia Schmoor; Martina Crysandt; Michael Heuser; Katharina S. Götze; Richard F. Schlenk; Konstanze Döhner; Helmut R. Salih; Gerhard Heil; Carsten Müller-Tidow; Wolfram Brugger; Andrea Kündgen; Maike de Wit; Aristoteles Giagounidis; Sebastian Scholl; Andreas Neubauer; Jürgen Krauter; Gesine Bug; Haifa Kathrin Al-Ali; Ralph Wäsch; Heiko Becker; Annette M. May; Justus Duyster; Björn Hackanson; Arnold Ganser; Hartmut Döhner; Michael Lübbert

doi:10.3324/haematol.2022.282258

Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Christoph Rummelt, Olga Grishina, Claudia Schmoor, Martina Crysandt, Michael Heuser, Katharina S. Götze, Richard F. Schlenk, Konstanze Döhner, Helmut R. Salih, Gerhard Heil, Carsten Müller-Tidow, Wolfram Brugger, Andrea Kündgen, Maike de Wit, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Jürgen Krauter, Gesine Bug, Haifa Kathrin Al-AliRalph Wäsch, Heiko Becker, Annette M. May, Justus Duyster, Björn Hackanson, Arnold Ganser, Hartmut Döhner, Michael Lübbert

Department of Internal Medicine III - Hematology and Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2244-2248
Number of pages	5
Journal	Haematologica
Volume	108
Issue number	8
DOIs	https://doi.org/10.3324/haematol.2022.282258
State	Published - Aug 2023

Access to Document

10.3324/haematol.2022.282258

Cite this

Rummelt, C., Grishina, O., Schmoor, C., Crysandt, M., Heuser, M., Götze, K. S., Schlenk, R. F., Döhner, K., Salih, H. R., Heil, G., Müller-Tidow, C., Brugger, W., Kündgen, A., de Wit, M., Giagounidis, A., Scholl, S., Neubauer, A., Krauter, J., Bug, G., ... Lübbert, M. (2023). Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER). Haematologica, 108(8), 2244-2248. https://doi.org/10.3324/haematol.2022.282258

@article{a9254d44f1b448c398df6404c584cf60,

title = "Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)",

author = "Christoph Rummelt and Olga Grishina and Claudia Schmoor and Martina Crysandt and Michael Heuser and G{\"o}tze, {Katharina S.} and Schlenk, {Richard F.} and Konstanze D{\"o}hner and Salih, {Helmut R.} and Gerhard Heil and Carsten M{\"u}ller-Tidow and Wolfram Brugger and Andrea K{\"u}ndgen and {de Wit}, Maike and Aristoteles Giagounidis and Sebastian Scholl and Andreas Neubauer and J{\"u}rgen Krauter and Gesine Bug and Al-Ali, {Haifa Kathrin} and Ralph W{\"a}sch and Heiko Becker and May, {Annette M.} and Justus Duyster and Bj{\"o}rn Hackanson and Arnold Ganser and Hartmut D{\"o}hner and Michael L{\"u}bbert",

note = "Funding Information: We wish to thank the members of the Independent Data Monitoring Committee for providing guidance during the trial. At the Clinical Trials Unit (Freiburg, Germany), we thank Caroline Cieslik for excellent organizational support and Angelika Gerlach and Inga Steinbrenner for assistance in statistical calculations. The study was supported by the German Federal Ministry of Education and Research (BMBF, Clinical Trials Program Grant No 01KG0913). Decitabine was provided by Janssen-Cilag, valproic acid was provided by TEVA. The study was further supported by the German Research Foundation (DFG consortia FOR2674, CRC992) for translational studies conducted by ML (A05, C04), HB (A05), HD (A02). Funding Information: The study was supported by the German Federal Ministry of Education and Research (BMBF, Clinical Trials Program Grant No 01KG0913). Decitabine was provided by Janssen-Cilag, valproic acid was provided by TEVA. The study was further supported by the German Research Foundation (DFG consortia FOR2674, CRC992) for translational studies conducted by ML (A05, C04), HB (A05), HD (A02).",

year = "2023",

month = aug,

doi = "10.3324/haematol.2022.282258",

language = "English",

volume = "108",

pages = "2244--2248",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "8",

}

Rummelt, C, Grishina, O, Schmoor, C, Crysandt, M, Heuser, M, Götze, KS, Schlenk, RF, Döhner, K, Salih, HR, Heil, G, Müller-Tidow, C, Brugger, W, Kündgen, A, de Wit, M, Giagounidis, A, Scholl, S, Neubauer, A, Krauter, J, Bug, G, Al-Ali, HK, Wäsch, R, Becker, H, May, AM, Duyster, J, Hackanson, B, Ganser, A, Döhner, H & Lübbert, M 2023, 'Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)', Haematologica, vol. 108, no. 8, pp. 2244-2248. https://doi.org/10.3324/haematol.2022.282258

TY - JOUR

T1 - Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia

T2 - results from a randomized 2x2 phase II trial (DECIDER)

AU - Rummelt, Christoph

AU - Grishina, Olga

AU - Schmoor, Claudia

AU - Crysandt, Martina

AU - Heuser, Michael

AU - Götze, Katharina S.

AU - Schlenk, Richard F.

AU - Döhner, Konstanze

AU - Salih, Helmut R.

AU - Heil, Gerhard

AU - Müller-Tidow, Carsten

AU - Brugger, Wolfram

AU - Kündgen, Andrea

AU - de Wit, Maike

AU - Giagounidis, Aristoteles

AU - Scholl, Sebastian

AU - Neubauer, Andreas

AU - Krauter, Jürgen

AU - Bug, Gesine

AU - Al-Ali, Haifa Kathrin

AU - Wäsch, Ralph

AU - Becker, Heiko

AU - May, Annette M.

AU - Duyster, Justus

AU - Hackanson, Björn

AU - Ganser, Arnold

AU - Döhner, Hartmut

AU - Lübbert, Michael

N1 - Funding Information: We wish to thank the members of the Independent Data Monitoring Committee for providing guidance during the trial. At the Clinical Trials Unit (Freiburg, Germany), we thank Caroline Cieslik for excellent organizational support and Angelika Gerlach and Inga Steinbrenner for assistance in statistical calculations. The study was supported by the German Federal Ministry of Education and Research (BMBF, Clinical Trials Program Grant No 01KG0913). Decitabine was provided by Janssen-Cilag, valproic acid was provided by TEVA. The study was further supported by the German Research Foundation (DFG consortia FOR2674, CRC992) for translational studies conducted by ML (A05, C04), HB (A05), HD (A02). Funding Information: The study was supported by the German Federal Ministry of Education and Research (BMBF, Clinical Trials Program Grant No 01KG0913). Decitabine was provided by Janssen-Cilag, valproic acid was provided by TEVA. The study was further supported by the German Research Foundation (DFG consortia FOR2674, CRC992) for translational studies conducted by ML (A05, C04), HB (A05), HD (A02).

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85166390839&partnerID=8YFLogxK

U2 - 10.3324/haematol.2022.282258

DO - 10.3324/haematol.2022.282258

M3 - Article

C2 - 36601981

AN - SCOPUS:85166390839

SN - 0390-6078

VL - 108

SP - 2244

EP - 2248

JO - Haematologica

JF - Haematologica

IS - 8

ER -

Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER)

Access to Document

Other files and links

Cite this